As an immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis.
Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.
[2] Sepsivac is approved by the Drug Controller General of India (DCGI) for treatment of sepsis or septic shock.
[3][better source needed] In patients with sepsis, in response to an infection, a lot of pro-inflammatory and anti-inflammatory cytokines are generated in the body.
In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled clinical trial to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients.